Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Orchestra BioMed (Nasdaq: OBIO) announced that Chairman and CEO David Hochman is scheduled to present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Orchestra BioMed (Nasdaq: OBIO) announced that Chairman and CEO David Hochman is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:00 a.m. ET in New Hope, Pennsylvania. The company also plans to host one-on-one investor meetings that day.
Details
Market move: OBIO -3.02% in the Aug 27 session. investment conference presentation
On Aug 27, the day this news came out, OBIO closed 3.02% below the previous close.
Data tracked by StockTitan Argus for the Aug 27 session.
Key Figures
- Conference edition
- 28th annual
- H.C. Wainwright Global Investment Conference
- Presentation date
- Sept. 16, 2026
- H.C. Wainwright conference
- Presentation time
- 9:00am ET
- Sept. 16, 2026
Historical Context
-
Wells Fargo conference presentation and one-on-one investor meetings were announced.
-
Quarterly results included program updates, strategic capital, and a reported net loss.
-
OBIO joined the Russell 3000 and Russell 2000 indexes.
-
Stock options covering 85,500 common shares were granted to five employees.
-
Jefferies conference participation and investor meetings were announced.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, Sept. 16, 2026 at 9:00am ET, and will also host one-on-one meetings with investors that day.
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Silas Newcomb
Orchestra BioMed
snewcomb@orchestrabiomed.com
Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.